Medaffcon Presented Insights from Finnish Real-World Data at European Lung Cancer Congress
Medaffcon's European Lung Cancer Congress (ELCC) poster showcased key findings from a recent study on non-small cell lung cancer (NSCLC).
Our website uses cookies and other similar tools. We also analyze anonymized web traffic. You can choose your cookie preferences below. You may choose only necessary cookies, specific cookies or all cookies. Read more in our privacy policy
Current topics and our latest news from the world of pharmaceuticals, healthcare and research.
Medaffcon's European Lung Cancer Congress (ELCC) poster showcased key findings from a recent study on non-small cell lung cancer (NSCLC).
Johan Rehnberg started working as a Scientific Advisor at Medaffcon’s Swedish office in August 2024. He is a dynamic researcher who values opportunities to learn new things and develop his skills – opportunities that Medaffcon provides.
The algorithm was originally developed to extract smoking status from patient texts with purpose to analyze the effects of smoking on postoperative complications. Today, it is also being utilized in lung cancer research.
Asthma and antibiotic use are linked to a higher risk of revision surgery in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This finding is based on a real-world evidence (RWE) study published in February.
Medaffcon provides skilled temporary workforce solutions for its client companies. An outsourced expert is a flexible solution to address a company's short-term resourcing challenges.
Medaffcon’s Market Access team welcomed a new leader in mid-November, as Simo Jääskeläinen returned to his familiar workplace after a six-year hiatus.
Medaffcon's operations in Sweden are well-established and growing, offering pharmaceutical companies RWE studies and Market Access services delivered by Data Scientists, Market Access experts, and RWE specialists working together.
In the coming years, breakthroughs in neurological and psychiatric drug research are expected to change treatment practices and significantly improve patients’ quality of life.
Finland will become an even more attractive place for conducting RWE (real-world evidence) research when it becomes a seamless part of the European Health Data Space (EHDS). Thus, health data can be used more efficiently across the European Union (EU), and datasets can be combined on an EU-wide basis.
Medaffcon has added Swedish healthcare registries to its capabilities as it continues to pursue growth and facilitate data utilisation by providing pharmaceutical companies access to rich and relevant healthcare data.
Real World Evidence (RWE) ecosystem in Finland Real world data (RWD) is defined by FDA…
Medicines in Finland are divided into medicines in ambulatory and hospital care. This article describes…